Please Login to participate

Course HomeCourse Progress
  • Pre-Test
  • Access Webinar
  • Evaluation
  • Certificate

Immunotherapeutic Management of Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors: Recent Developments and Challenges

FACULTY

Andrew Haas, MD, PhD
Director, Interventional Pulmonary and Thoracic Oncology
Director, Bronchoscopy
Hospital of the University of Pennsylvania,
University of Pennsylvania Health System

Marina Garassino, MD
Chief of the Thoracic Oncology Unit
Instituto Nazionale dei Tumori

Aaron Lisberg, MD
Assistant Professor of Medicine
University of California, Los Angeles

Jamie E. Chaft, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center

CONTINUING EDUCATION

 

In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

INTENDED LEARNERS

This educational activity is designed to meet the educational needs of medical oncologists, nurses, nurse practitioners, physician assistants, pathologists, pulmonologists, oncology pharmacists, researchers, internists wishing to have an update on the diagnosis and management of lung cancer, and other healthcare professionals interested in the care and treatment of patients with thoracic malignancies.

 

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

  • Describe the mechanisms, efficacy, and safety of new and emerging ICI agents and combinations
  • Integrate ICIs into evidence-based, personalized therapeutic strategies across treatment settings
  • Develop strategies to overcome common clinical challenges associated with ICI therapies

CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: December 14, 2021
Expiration Date: December 14, 2022
Estimated Time to Complete: 1.00 hour

There is no fee associated with this activity.

PHYSICIANS

NACCME designates this internet live/enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING

This continuing nursing education internet live/enduring activity awards 1.00 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour. 

NURSE PRACTITIONER

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

PHARMACY

This internet live/enduring, knowledge-based activity (Universal Activity Number: UAN JA0006201-0000-21-231-H01-P) has been approved for a maximum of 1.00 contact hours (0.10 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

FACULTY

The faculty has reported the following:

Marina Garassino: Other - AstraZeneca, MSD International GmbH, Bristol Myers Squibb, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda Pharmaceuticals, Seattle Genetics, Mirati, Daiichi Sankyo, Regeneron, Tiziana, Foundation Medicine, GlaxoSmithKline, Spectrum Pharmaceuticals, AIRC, AIFA, Italian Moh, TRANSCAN, Research Fundings

Andrew HaasConsultant - Bristol Myers Squibb, Olympus America, Inc., Serpex Medical ; Advisory Board - Novocure, VisionAir

Aaron LisbergAdvisory Board/Consultant - AstraZeneca, Bristol-Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, Morphosys, Eli-Lilly, Oncocyte, Novartis; Grant/Research Support - Daiichi Sankyo, Calithera Biosciences, AstraZenaca, Dracen Pharmaceuticals, WindMIL; Other - Boston Scientific

Jamie E. ChaftConsultant - AstraZeneca, Bristol Myers Squibb, Flame Biosciences, Genentech, Guardant Health, Jansen, Merck, Novartis, Regeneron

PLANNING COMMITTEE

In addition to the faculty listed above, NACCME planners and staff include Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Kathleen Hines, and Dena Moftah.

No planner has disclosed a relevant financial relationship with any commercial interest.

 

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.

COMMERCIAL SUPPORT

The following company(ies) have provided an educational grant in support of this activity:

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme